leucine rich repeats and immunoglobulin like domains 3Genealiases: []
Q-omics provides the consensus-scored LRIG3 profile across patient tissues and cancer cell-line models. LRIG3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LRIG3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LRIG3 RNA expression shows 19,123 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRC, and THYM as cancer lineages where LRIG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRIG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRIG3 survival associations across molecular data types. LRIG3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRIG3 RNA expression–survival associations across cancer types. High LRIG3 expression shows unfavorable associations in KIRP and CHOL, but favorable associations in UCS, KIRC, HNSC and LAML. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for LRIG3 RNA expression.
This table summarizes LRIG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LRIG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRIG3 shows lower tumor expression in BRCA and UCEC and higher tumor expression in KIRC, HNSC, LUSC and CHOL. The KIRC box plot shows higher LRIG3 RNA expression in tumor versus normal tissue (log2 FC = +0.936, t-test p < 0.001).
This table shows molecular features associated with LRIG3 in patient tissues and cancer cell lines. In patient samples, LRIG3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRIG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
